Improving Radiation Treatment for Pancreatic Cancer with Targeted Nanoparticles
In situ cancer cell specific biomineralization to overcome nanoparticle delivery barriers and sensitize pancreatic cancer to radiotherapy
This work explores a new way to deliver tiny particles directly to pancreatic cancer cells, aiming to make radiation therapy more effective for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11132625 on NIH RePORTER |
What this research studies
Pancreatic cancer is very difficult to treat because tumors are often protected by a dense barrier. This project looks at a clever method where cancer cells are encouraged to create their own tiny gold particles right inside the tumor. These particles can then help radiation therapy work better by increasing the radiation dose specifically within the cancer cells, while hopefully sparing healthy tissues. This approach aims to get past the tumor's protective barrier without destroying it, which could lead to more powerful and precise treatments.
Who could benefit from this research
Good fit: This foundational work is for patients with pancreatic cancer, particularly those who may benefit from intensified radiation therapy.
Not a fit: Patients whose cancer does not respond to radiation therapy or those with other cancer types may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this approach could make radiation therapy much more effective for pancreatic cancer patients, potentially leading to better outcomes.
How similar studies have performed: The concept of in situ biomineralization by cancer cells is a recently reported and novel strategy, building on existing knowledge of nanoparticle radiosensitization.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Sokolov, Konstantin V — University of Tx Md Anderson Can Ctr
- Study coordinator: Sokolov, Konstantin V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.